[ÇÑÅõÁõ±Ç ÁøÈ«±¹] Á¦¾à/¹ÙÀÌ¿À µ¥Àϸ® ´º½º
¾È³çÇϼ¼¿ä ÇÑÅõÁõ±Ç Á¦¾à¹ÙÀÌ¿À ÁøÈ«±¹ÀÔ´Ï´Ù.
¢º️ÀüÀÏ ¹Ì±¹ ÁÖ¿ä À妽º
* ´Ù¿ì +0.1% S&P Á¦¾à +0% ³ª½º´Ú ¹ÙÀÌ¿À +0.2%
¢º️ÇØ¿Ü Peer ÀüÀÏ ÁÖ°¡
* ¼¿Æ®¸®¿Â °ü·Ã: Pfizer +0.1% J&J -1.3% Teva -2.8% Mylan -0.3%
* »ï¼º¹ÙÀÌ¿À °ü·Ã: Lonza +0.7% Merck -0.2% Roche +0% Amgen -1.4% Biogen +0.5%
* Çѹ̾àÇ° °ü·Ã: Sanofi +1.1% Spectrum -2.5%
* º¸Å彺: Allergan -0.3% Revance Therapeutic +1% Evolus -2.7%
* ±âŸ: Gilead Science -0.2% Regeneron -0.5% Abbvie -0.8% Celgene -0.8% Eli Lilly +0.4% CSL -1.3%
¢º️±¹³» À̽´
* Ç︯½º¹Ì½º "9¿ù¸» ÇÙ½É 3»ó ¼ºÆÐ °ø°³...ºòµô ±â´ë"
* ¼¿Æ®¸®¿ÂÇコÄɾî, È£ÁÖÁ¦¾àÇùȸ °¡ÀÔ 'ó¹æ ź·Â'
* Å©¸®½ºÅ», ½ºÀ§½º ¹ÙÀÌ¿ÀÅõÀÚ»ç ¡®¹ëºä¡¯¿Í MOU
* ¾¾Á¦ÀÌÇコÄÉ¾î ½Å¾à ÄÉÀÌĸ, Ãâ½Ã 4°³¿ù ¸¸¿¡ ó¹æ¾× 80¾ï µ¹ÆÄ
* Á¤ºÎ, À¯È¿¹°Áú ¹ß±¼ºÎÅÍ ÀÓ»ó2»ó±îÁö¡¥"½Å¾à°³¹ß ¿ÃÀÎ" 3.5Á¶ ÅõÀÔ
* Á¾±Ù´ç, ½ÉÇ÷°ü°èÁúȯ Ä¡·áÁ¦ ÀÓ»ó½ÃÇè '¼øÇ×'
* ´ë¿õ¹ÙÀÌ¿À 'º£¾Æ¼ÁÆ®', µµ³×ÆäÁú Á¦³×¸¯ 1À§ µî±Ø
¢º️ÇØ¿Ü À̽´
* ¾ÏÁ¨-¿¤·¯°£, ¾Æºñ½ºÆ¾¡¤Çã¼Áƾ BS Ú¸¼ ù Ãâ½Ã
* ³×¿ÂÅ׶óǻƽ½º, ½ÅÇ׿ø ¾Ï¹é½Å 1b»ó¼ ¡®PFS °³¼±¡¯
* ³ë¹ÙƼ½º, °âÇüÀûÇ÷±¸Áõ Ä¡·áÁ¦ ¡®Å©¸®Àܸ®ÁÖ¸¿¡¯ BLA Á¦Ãâ
* ¡®ÀÓÇÉÁö¡¯ ÃÑ »ýÁ¸±â°£ ó¹æÁ¤º¸ »ðÀÔ FDA ½ÂÀÎ
* Amarin's $400M-plus offering put investors on edge. Is a buyout off the table?
|